You cannot register for this webinar

Calidi Biotherapeutics is a clinical-stage biotechnology company that is transforming cancer treatment with innovative oncolytic virotherapies designed for both systemic and localized administrations. Our technology, which includes cell-based and enveloping technology, protects and delivers tumor-killing viruses into tumor sites, effectively overcoming clinical challenges and transforming the tumor microenvironment. This makes it an ideal technology as a monotherapy, or in combination with other immunotherapies designed to attack solid tumors. We have developed 3 distinct platforms: • RTNova (CLD-400) for lung cancers and disseminated solid tumors (preclinical), is Calidi's systemic breakthrough technology, announced in February 2024. RTNova uses enveloped virotherapies, delivered systemically. • Neuronova (CLD-101) for High-grade glioma (Clinical stage) • Supernova (CLD-201) for multiple solid tumors (IND enabling) RTNova shows promising potential in targeting advanced metastatic disease across the body, while maintaining survival in the bloodstream. Preclinical models have demonstrated RTNova's efficacy in transforming tumor immune microenvironments and eradicating distant and diverse tumors. In addition, the program exhibits synergistic potential with other immunotherapies, including cell therapies, enhancing its ability to attack and eliminate disseminated solid tumors.